Vontobel Holding’s aTyr Pharma ATYR Stock Holding History

Vontobel Holding’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,000	Closed	-$64.8K	–	1140
2023 Q2	$64.8K	Buy	+30,000	New	+$65.5K	﹤0.01%	1065

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vontobel Holding's ATYR Position: Q3 2023 in Review

Vontobel Holding sold out of aTyr Pharma (ATYR) in Q3 2023, closing a stake of 30,000 shares — an estimated $64.8K sold.

Vontobel Holding first reported a position in ATYR in Q2 2023 and held it in 1 quarter. The position peaked at $64.8K in Q2 2023. 40 funds tracked by Wall St. Rank hold ATYR as of Q3 2023.

Vontobel Holding reported no remaining aTyr Pharma position as of Q3 2023 after selling out during the quarter.
Vontobel Holding sold 30,000 aTyr Pharma shares in Q3 2023, an estimated $64.8K.
Vontobel Holding first reported a position in aTyr Pharma in Q2 2023 and held it in 1 quarter.
Vontobel Holding's aTyr Pharma position peaked at $64.8K in Q2 2023.
40 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2023.

Based on Vontobel Holding's 13F filing for Q3 2023, filed 11 Oct 2023.